➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson
Baxter
Medtronic
Mallinckrodt
Moodys

Last Updated: September 18, 2020

DrugPatentWatch Database Preview

Litigation Details for Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Small Molecule Drugs cited in Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc.
The small molecule drug covered by the patents cited in this case is   Start Trial .

Details for Par Pharmaceutical Inc. v. Breckenridge Pharmaceutical Inc. (D. Del. 2015)

Date Filed Document No. Description Snippet Link To Document
2015-11-11 1 infringes U.S. Patent Nos. 6,592,903 (the “’903 Patent”) and 7,101,576 …infringement of U.S. Patent Nos. 9,101,540 (the “’540 Patent”), 9,101,549 (the “’549 Patent”), and 9,107,8279,107,827 (the “’827 Patent”) (collectively, the “Patents-in-Suit”) pursuant to the Patent Laws of the United…IV Certification”). The ’903 and ’576 Patents, like the Patent-in-Suit, cover Par’s Megace® ES drug product…owner of the ’540, ’549, and ’827 Patents. 16. The ’540 Patent, entitled “Nanoparticulate Megestrol External link to document
2016-01-25 13 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 9,101,540 B2; 9,101,549 B2; 9,107,827…2015 25 January 2016 1:15-cv-01039 830 Patent None District Court, D. Delaware External link to document
2015-11-11 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) US 9,101,540 B2; US 9,101,549 …2015 25 January 2016 1:15-cv-01039 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
AstraZeneca
Medtronic
Moodys
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.